Skip to Content
Merck
  • Biosilicate® and low-level laser therapy improve bone repair in osteoporotic rats.

Biosilicate® and low-level laser therapy improve bone repair in osteoporotic rats.

Journal of tissue engineering and regenerative medicine (2010-10-07)
Paulo Sérgio Bossini, Ana Claudia Muniz Rennó, Daniel Araki Ribeiro, Renan Fangel, Oscar Peitl, Edgar Dutra Zanotto, Nivaldo Antonio Parizotto
ABSTRACT

The aim of this study was to investigate the effects of a novel bioactive material (Biosilicate®) and low-level laser therapy (LLLT) on bone fracture consolidation in osteoporotic rats. Forty female Wistar rats were submitted to ovariectomy (OVX) to induce osteopenia. Eight weeks after surgery, the animals were randomly divided into four groups of 10 animals each: a bone defect control group (CG); a bone defect filled with Biosilicate group (BG); a bone defect filled with Biosilicate and irradiated with LLLT at 60 J/cm(2) group (BG60); and a bone defect filled with Biosilicate and irradiated with LLLT at 120 J/cm(2) group (BG120). Bone defects were surgically performed on both tibias. The size of particle used for Biosilicate was 180-212 µm. Histopathological analysis showed that bone defects were predominantly filled with the biomaterial in specimens treated with Biosilicate. LLLT with either 60 or 120 J/cm(2) was able to increase collagen, Cbfa-1, VGEF and COX-2 expression in the circumjacent cells of the biomaterial. A morphometric analysis revealed that the Biosilicate + laser groups showed a higher amount of newly formed bone. Our results indicate that laser therapy improves bone repair process in contact with Biosilicate as a result of increasing bone formation, as well as COX-2 and Cbfa-1 immunoexpression, angiogenesis and collagen deposition in osteoporotic rats.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Direct Red 80, Dye content 25 %